Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Fulvestrant”

364 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 364 results

Testing effectiveness (Phase 2)Ended earlyNCT00138125
What this trial is testing

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Who this might be right for
Breast Cancer
Translational Oncology Research International 2
Testing effectiveness (Phase 2)Ended earlyNCT03241810
What this trial is testing

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Elevation Oncology 22
Testing effectiveness (Phase 2)UnknownNCT05792410
What this trial is testing

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Who this might be right for
HER2 Low Advanced or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 300
Testing effectiveness (Phase 2)Study completedNCT00234403
What this trial is testing

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 60
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Early research (Phase 1)Study completedNCT03324061
What this trial is testing

Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration

Who this might be right for
Pharmacokinetics
Eagle Pharmaceuticals, Inc. 600
Testing effectiveness (Phase 2)Study completedNCT00334295
What this trial is testing

Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

Who this might be right for
Endometrial Carcinoma
AstraZeneca 35
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Testing effectiveness (Phase 2)UnknownNCT05075512
What this trial is testing

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasm Female
Zhejiang Cancer Hospital 40
Testing effectiveness (Phase 2)UnknownNCT00927511
What this trial is testing

A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)

Who this might be right for
Breast Cancer
Regina Elena Cancer Institute 104
Early research (Phase 1)Not Yet RecruitingNCT07366632
What this trial is testing

Single Dose of BL0175 in Postmenopausal Women

Who this might be right for
Postmenopausal Women
Shanghai Best-Link Bioscience, LLC 27
Testing effectiveness (Phase 2)UnknownNCT02530411
What this trial is testing

Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer

Who this might be right for
Neoplasms
Velindre NHS Trust 160
Testing effectiveness (Phase 2)Study completedNCT00754325
What this trial is testing

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Who this might be right for
Advanced Breast Cancer
Bristol-Myers Squibb 100
Early research (Phase 1)WithdrawnNCT01004419
What this trial is testing

Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non Small Cell Lung
University of Wisconsin, Madison
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)Study completedNCT03926936
What this trial is testing

FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study

Who this might be right for
Endometrial Stromal SarcomaAdenosarcoma of UterusLeiomyosarcoma Uterus+3 more
Frederic Amant 17
Large-scale testing (Phase 3)Study completedNCT00241449
What this trial is testing

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Breast CancerMetastasis
AstraZeneca 51
Testing effectiveness (Phase 2)Study completedNCT01560416
What this trial is testing

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 50
Early research (Phase 1)Study completedNCT02392611
What this trial is testing

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Who this might be right for
Solid Tumors and Lymphomas
Gilead Sciences 33
Next Page